TransCode reports positive phase 1 trial progress for cancer therapy
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 million, has announced the progression of its Phase 1 clinical trial with ...
BioCardia completes enrollment in low dose cohort in CardiALLO Phase I/II trial
BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy ...
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...
Benzinga.com21d
TransCode Therapeutics Shares Are Surging Today: What's Going On?
The pharmacokinetic data from these cohorts has been consistent with preclinical and Phase 0 trial results. Patients from the earlier cohorts remain in the study and are continuing to receive ...
Morningstar8d
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode ...
Finanznachrichten8d
TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode ...